InfuSystem Holdings, Inc. announced that two electronic infusion pumps used in its Pain Management services will receive separate payment under the NOPAIN Act starting January 1, 2026.
This decision by CMS is a pivotal step towards enhancing access to clinically proven non-opioid treatments for Medicare beneficiaries in outpatient settings.
The company's CEO expressed optimism about the expanded reimbursement and potential growth in the Pain Management business.
Expanded Payment Eligibility
The CADD-Solis TM and Sapphire TM infusion pumps are now eligible for separate Medicare reimbursement under the NOPAIN Act, encouraging adoption by healthcare providers.
Impact on Business Strategy
This rule change may act as a catalyst for volume growth in InfuSystem's Pain Management business by promoting safer pain management alternatives.
Long-Term Outlook
The company remains cautiously optimistic and will closely monitor reimbursement requirements and customer adoption to assess the impact on future growth.
- CMS's decision to approve separate payment for non-opioid treatments under the NOPAIN Act is significant for InfuSystem's Pain Management services.
- The inclusion of the CADD-Solis TM and Sapphire TM infusion pumps in the reimbursement program enhances the company's competitive position in the market.
The approval for separate payment of infusion pumps underscores InfuSystem Holdings' commitment to promoting safer pain management solutions and aligning with CMS's efforts to address the opioid crisis.